Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

Raya Aliakbar; Olga Manouvakhova; Cindy Wong; Myo Htut; Johannes Pulst-Korenberg; Murali Janakiram; Michael Rosenzweig; Scott R. Goldsmith; Xenos L. Mason

doi:10.3389/fimmu.2024.1444010

Frontiers in Immunology (Sep 2024)

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

Raya Aliakbar,
Olga Manouvakhova,
Cindy Wong,
Myo Htut,
Johannes Pulst-Korenberg,
Murali Janakiram,
Michael Rosenzweig,
Scott R. Goldsmith,
Xenos L. Mason

Affiliations

Raya Aliakbar: Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
Olga Manouvakhova: Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
Cindy Wong: Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
Myo Htut: Division of Multiple Myeloma, Department of Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, United States
Johannes Pulst-Korenberg: Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States
Murali Janakiram: Division of Multiple Myeloma, Department of Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, United States
Michael Rosenzweig: Division of Multiple Myeloma, Department of Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, United States
Scott R. Goldsmith: Division of Multiple Myeloma, Department of Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, United States
Xenos L. Mason: Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States

DOI: https://doi.org/10.3389/fimmu.2024.1444010
Journal volume & issue: Vol. 15

Abstract

Read online

We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of a successful symptomatic treatment of this well-described neurotoxic syndrome.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords